The unmet need: why sickle cell disease still demands better oral therapies

Sickle cell disease remains one of the most prevalent inherited haemoglobin disorders globally, with its burden concentrated in sub-Saharan Africa and South Asia. Hydroxyurea, the mainstay oral therapy for decades, induces fetal hemoglobin (HbF) through a cytoreductive and nitric oxide-mediated mechanism — but a clinically significant subset of patients either do not respond adequately or cannot tolerate its genotoxic effects. According to clinical reviews indexed in PatSnap’s literature database, this hydroxyurea-refractory population represents a persistent gap that novel HbF inducers are designed to address.

Public health analyses highlight that the oral route of administration is a critical accessibility advantage in low-resource settings where gene therapy infrastructure — conditioning regimens, cell processing facilities, specialised haematology centres — does not exist. A paper by Piel et al. (2023) reviewed in PatSnap’s literature corpus argues that tiered pricing and oral formulation strategies are essential to translating therapeutic advances into population-level benefit for sickle cell disease. This framing positions etavopivat not merely as a clinical asset but as a potential global health tool, provided its Phase 2/3 data support regulatory approval.

The case for a non-genotoxic alternative is particularly strong in paediatric populations. Patent filings from Forma Therapeutics (US20220313658A1) specifically address erythroid-targeted PKR activation in children and adolescents with sickle cell disease, emphasising the safety profile advantages of a non-cytotoxic HbF inducer for patients who may require decades of continuous therapy.

How etavopivat reactivates fetal hemoglobin without editing the genome

Etavopivat induces fetal hemoglobin by activating pyruvate kinase R (PKR) in erythroid progenitor cells, triggering a cascade of metabolic changes that ultimately favour γ-globin over β-globin gene expression — and it does so without modifying a single nucleotide of the patient’s DNA. The mechanism begins with PKR activation reducing levels of 2,3-diphosphoglycerate (2,3-DPG), a glycolytic intermediate that accumulates abnormally in sickle red blood cells. This reduction shifts cellular energy metabolism and improves red blood cell deformability and lifespan.

The downstream effect on γ-globin expression is the result of what mechanistic researchers describe as metabolic-epigenetic reprogramming. A study by Giarratana et al. (2024) demonstrated in vitro and in murine models that PKR activation in erythroid progenitor cells creates conditions that favour γ-globin over β-globin gene expression, without requiring modification of the hemoglobin genes or their regulatory elements. This distinguishes etavopivat sharply from CRISPR-based approaches — such as exagamglogene autotemcel — which disrupt the BCL11A enhancer to permanently silence the HbF-to-HbA switch, as described in research published by organisations including the Broad Institute.

Pharmacokinetic and pharmacodynamic studies (Xu et al., 2022) characterised etavopivat’s oral bioavailability, a plasma half-life of approximately 10–12 hours, and a dose-dependent relationship between PKR target engagement and HbF induction. The time-course data show that 2,3-DPG reduction precedes HbF increases, consistent with the proposed metabolic-epigenetic sequence. Research published in journals indexed by NIH PubMed has further contextualised how erythroid progenitor stage and metabolic state collectively determine the γ-globin:β-globin ratio, supporting the biological plausibility of PKR activation as a pharmacological hemoglobin switching strategy.

“PKR activation in erythroid progenitor cells creates conditions that favour γ-globin over β-globin gene expression without requiring modification of the hemoglobin genes or their regulatory elements — distinguishing etavopivat from all gene editing approaches.”

Importantly, the mechanism does not involve BCL11A inhibition directly. Reviews by Orkin et al. (2023) describe PKR-mediated metabolic reprogramming as a BCL11A-independent pathway to HbF induction — meaning etavopivat’s activity is mechanistically orthogonal to CRISPR-based BCL11A enhancer disruption and could theoretically be combined with BCL11A-targeting agents for additive effect, a hypothesis that remains to be tested clinically.

Phase 2 efficacy data and the PEARL Phase 2/3 trial design

Phase 2 clinical results of etavopivat demonstrated a statistically significant mean increase of 6.2 percentage points in HbF from baseline in adult and adolescent patients with sickle cell disease. The study, reported by Brandow et al. (2023), also showed reductions in haemolysis markers — including lactate dehydrogenase (LDH), indirect bilirubin, and reticulocyte counts — alongside improved red blood cell deformability and a favourable safety profile. Earlier mechanistic studies reported HbF increases of 4–8 percentage points across early-phase trial cohorts.

The PEARL trial, described by Kutlar et al. (2023), is the pivotal Phase 2/3 study designed to support regulatory submission. It enrols adult and adolescent patients with the HbSS and HbSβ0-thalassemia genotypes — the most clinically severe forms of sickle cell disease — and evaluates etavopivat at once-daily oral doses. The trial’s two co-primary endpoints are the annualised rate of vaso-occlusive crises (VOC) and the percentage increase in HbF. VOC reduction is clinically meaningful because vaso-occlusive pain episodes are the leading cause of emergency hospital visits and long-term organ damage in sickle cell disease patients, as documented in guidelines from NHLBI.

Companion diagnostic work (WO2022150440A1, Forma Therapeutics) has proposed biomarker panels — including 2,3-DPG levels, reticulocyte counts, and erythroid progenitor markers — for stratifying patients most likely to respond to etavopivat. This companion diagnostic approach, if validated in PEARL, would enable precision prescribing and potentially support label claims for specific patient subpopulations.

Novo Nordisk’s patent portfolio: from Forma Therapeutics acquisition to pipeline expansion

Novo Nordisk now holds the etavopivat IP estate following its acquisition of Forma Therapeutics, and the breadth of its patent filings reveals a strategy that extends well beyond the initial sickle cell disease indication. The core Forma Therapeutics patents — including US11400085B2, covering PKR activator use in sickle cell disease and related complications, and WO2021202965A1, covering Phase 1/2 clinical dosing methods — form the foundation. Novo Nordisk has since filed a series of continuation and expansion patents that cover dosing optimisation, formulation, combination therapy, and expanded indications.

Key Novo Nordisk filings include US20230338342A1 (optimised once-daily oral dosing at 400 mg and 600 mg), US20240058297A1 (crystalline polymorphic forms of etavopivat optimised for bioavailability and stability), WO2023278553A1 (combination strategies with additional HbF-inducing agents in sickle cell disease and beta-thalassemia), and WO2024011149A1 (VOC reduction as a primary clinical endpoint, covering adult, adolescent, and paediatric populations). The crystalline forms patent is particularly significant for commercial manufacturing: solid-state characterisation using XRPD, DSC, and TGA data is designed to provide regulatory-grade control of the once-daily oral tablet formulation.

Novo Nordisk has also filed US20230149376A1 covering PKR activator use in beta-thalassemia and related hemoglobin disorders, signalling an intent to expand etavopivat beyond sickle cell disease. This is consistent with the mechanism: ineffective erythropoiesis in beta-thalassemia creates a different but related context in which PKR activation and HbF induction may provide clinical benefit. According to WHO estimates, beta-thalassemia affects hundreds of thousands of patients globally, representing a substantial secondary market for a validated PKR activator.

Positioning etavopivat in the broader HbF-switching landscape

Etavopivat occupies a distinct niche in the sickle cell disease therapeutic landscape: it is neither the established standard of care (hydroxyurea) nor a one-time curative gene therapy, but a non-genotoxic, non-editing oral agent that offers a pharmacological route to hemoglobin switching. Understanding its competitive position requires mapping it against three categories of HbF-reactivation strategy: cytoreductive agents, gene editing therapies, and emerging pharmacological HbF inducers.

Hydroxyurea: established but limited by genotoxicity and non-response

Hydroxyurea induces HbF through a combination of cytoreduction, nitric oxide generation, and stress erythropoiesis. Its genotoxic mechanism — while clinically manageable in most adults — raises concerns for long-term paediatric use and creates a non-response population in which the cytoreductive effect does not translate to adequate HbF induction. Etavopivat’s non-cytotoxic mechanism is explicitly positioned as an advantage in this context, both in Forma Therapeutics’ original patent filings (US20220313658A1) and in Novo Nordisk’s subsequent combination therapy applications (US20220193039A1, WO2023278553A1).

Gene editing therapies: curative but not universally accessible

CRISPR-based therapies such as exagamglogene autotemcel (CTX001) represent a potentially curative approach, disrupting the BCL11A enhancer to permanently reactivate HbF. The CLIMB SCD-121 Phase 3 study, reviewed in PatSnap’s literature database, frames etavopivat as a non-curative but accessible oral pharmacological alternative for the large patient population that cannot access gene therapy infrastructure. The comparison is not one of efficacy head-to-head, but of accessibility, risk profile, and healthcare system requirements. Gene editing requires myeloablative conditioning, specialised cell therapy manufacturing, and long-term follow-up — barriers that are prohibitive in the low-resource settings where sickle cell disease burden is highest.

Emerging pharmacological HbF inducers: a crowded but differentiated space

Beyond etavopivat, the non-editing pharmacological HbF-induction space includes BCL11A small molecule inhibitors (Fulcrum Therapeutics, US20230159500A1), LIN28 pathway modulators (Boston Children’s Hospital, WO2023215368A1), and NFIX transcription factor inhibitors (St. Jude Children’s Research Hospital, US20240082218A1). Each targets a different node in the γ-globin regulatory network. Etavopivat’s differentiator is its upstream metabolic mechanism: by acting at the PKR/2,3-DPG/erythroid metabolism level rather than directly at transcription factors, it may complement — rather than compete with — BCL11A-targeting agents, a combination hypothesis supported by Novo Nordisk’s WO2023278553A1 filing.

Biomarker-guided patient selection, covered in Forma Therapeutics’ WO2022150440A1, may further sharpen etavopivat’s competitive positioning by identifying the subpopulation most likely to achieve clinically meaningful HbF increases. If PEARL validates a companion diagnostic approach alongside VOC reduction, etavopivat would enter the market with a precision medicine label that differentiates it from hydroxyurea’s population-level prescribing paradigm. The patent and clinical data reviewed through PatSnap’s life sciences intelligence platform suggest that the competitive landscape for non-editing HbF inducers is intensifying, with multiple mechanistic classes advancing simultaneously toward clinical proof-of-concept.